1. 5944Mortality advantage of mitraclip in patients with heart failure and mitral regurgitation: an updated meta-analysis
- Author
-
M D Verma Diva Ratyan, M D Bhavi Pandya, and Moses Ashukem
- Subjects
Mitral regurgitation ,medicine.medical_specialty ,business.industry ,MitraClip ,Heart failure ,Meta-analysis ,Internal medicine ,medicine ,Cardiology ,In patient ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business - Abstract
Background In patients with symptomatic mitral regurgitation who are high risk for surgery, transcatheter mitral-valve repair has been shown to be safe and improve clinical outcomes. However, its impact on survival has shown conflicting results in recent trials. Methods PubMed, EMBASE and Google Scholar databases were queried for all trials about MitraClip compared with optimal medical therapy Results This meta-analysis of 9 trials including 3199 patients, found that patients treated with MitraClip compared to optimal medical therapy had similar 30-day mortality (OR 0.64, 95% CI 0.32- 1.28) while at 12-months MitraClip was associated with significantly lower all-cause mortality (OR 0.46, 95% CI 0.33- 0.65). Absolute risk reduction was 13.9% and number needed to treat to save 1 life at 12 months was 7.2. Figure 1 Conclusions In this meta-analysis, transcatheter mitral valve repair with MitraClip was associated with significantly lower mortality at 12 months of follow up
- Published
- 2019
- Full Text
- View/download PDF